Improvements in systemic cancer treatments have resulted in more patients surviving for
prolonged periods of time on treatment. This has made treatment-related toxicity and quality …

Drug delivery nanosystems (DDnS) is widely developed recently. Gelatin is a high-potential
biomaterial originated from natural resources for anticancer DDnS, which can effectively …

Colorectal cancer (CRC) is one of the most common forms of cancer, with an estimated 1.36
million new cases and almost 700,000 deaths annually. Approximately 21% of patients with …

Mucoadhesive drug delivery systems (DDS) may promote safer chemotherapy for colorectal
cancer (CRC) by maximizing local drug distribution and residence time. Carbohydrate …

Background Hand–foot syndrome (HFS) is a common side-effect of capecitabine. S-1 is an
oral fluoropyrimidine with comparable efficacy to capecitabine in gastrointestinal cancers but …

Purpose Despite advances in the treatment of colorectal cancer, third-line treatment options
are still limited. Regorafenib was approved in 2012 for the treatment of patients with …

Background S-1 is an oral fluoropyrimidine that is increasingly used in Western countries for
the treatment of metastatic colorectal cancer (mCRC). We conducted a non-inferiority meta …

Background The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for
refractory metastatic colorectal cancer patients. We assessed the feasibility and …

Accumulating evidence indicates that alterations in glial activation and disturbances in glial
glutamate metabolism may contribute to the pathogenesis of amyotrophic lateral sclerosis …

Background Fluoropyrimidines (FPs) are an essential part of the majority of systemic
regimens in the treatment of metastatic colorectal cancer (CRC). The use of the oral FP S-1 …